A study revealed that critically ill patients with Vitamin D deficiency do not appear to benefit from the enteral treatment with high-dose Vitamin D3 in terms of global cognition or executive function.
 |
| Photo: Enteral Vitamin D Treatment | InStyleHealth |
Research randomized 95 vitamin-D deficient, critically ill patients to receive a single high-dose (540,000 IU) enteral treatment of vitamin D3 to 47 patients or placebo to 48 individuals shortly after hospital admission.
Efficacy outcomes were global cognition using the Repeatable
Battery for the Assessment of Neuropsychological Status (RBANS) and executive
function which is being assessed using a composite score derived from three
Delis – Kaplan Executive Function System subscales.
Evaluations were facilitated at an average of 443 days
after randomization and compared using multivariable proportional odds
regression.
Findings revealed that enteral vitamin D3 treatment
produced a significant improvement in neither global cognition nor executive
function. Adjusted average RBANS score at follow-up was 79.6 in the vitamin D3
group vs 82.1 in the placebo group.
Similarly, the adjusted average executive function
composite score was similar in the treatment groups, with an aOR of 0.72. For
complete details of the clinical research, click here.
Source: Chest 2021;doi:10.1016/j.chest.2021.03.046